3-FMA

hypertension, coronary artery disease, arrhythmias, cardiomyopathy, congestive heart failure

3-FMA releases norepinephrine and dopamine, producing dose-dependent vasoconstriction, tachycardia, and hypertension. Pre-existing cardiovascular conditions — including hypertension, coronary artery disease, arrhythmias, cardiomyopathy, and congestive heart failure — are subject to acute exacerbation. Risk of hypertensive crisis, cardiac arrhythmia, and myocardial ischemia.

3-FMA is expected to lower seizure threshold, particularly in combination with other seizure-risk medications. Individuals with epilepsy or other seizure disorders face elevated risk of breakthrough seizures.

schizophrenia, schizoaffective disorder, substance-induced psychosis history

Amphetamine-class compounds can precipitate or exacerbate psychotic episodes through excessive dopaminergic stimulation. Individuals with schizophrenia, schizoaffective disorder, or history of substance-induced psychosis face elevated risk.

Stimulant compounds can trigger manic episodes in individuals with bipolar disorder. 3-FMA's monoamine-releasing mechanism creates risk of mania precipitation, particularly during the peak phase.

3-FMA metabolism is inferred to proceed primarily through CYP2D6. Hepatic impairment may reduce metabolic clearance, increasing parent compound AUC and prolonging duration of action and toxicity exposure.

Hyperthyroidism increases sensitivity to catecholamines. Combined with 3-FMA's catecholamine-releasing mechanism, this creates compounded cardiovascular strain and hyperthermia risk.

Stimulant-induced vasoconstriction may compromise placental blood flow. No reproductive toxicity data exist for 3-FMA. Fetal exposure via transplacental passage and excretion into breast milk are expected based on the compound's physicochemical properties (small, lipophilic, basic amine).

Approximately 5–10% of Caucasian populations are CYP2D6 poor metabolizers. By analogy with PMMA — where CYP2D6 poor metabolizer genotype has been directly linked to fatal intoxications — 3-FMA poor metabolizers may experience elevated exposure, prolonged duration, and increased neurotoxicity and cardiovascular risk.

phenelzine, tranylcypromine, moclobemide, selegiline, harmine, harmaline

Co-administration of 3-FMA with any monoamine oxidase inhibitor — including irreversible inhibitors (phenelzine, tranylcypromine), reversible inhibitors (moclobemide), and plant-derived MAOIs (harmine, harmaline) — prevents enzymatic breakdown of the monoamines released by 3-FMA. This produces potentially fatal accumulation of serotonin, dopamine, and norepinephrine, manifesting as serotonin syndrome and/or hypertensive crisis.

fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, desvenlafaxine

SSRIs and SNRIs add serotonergic burden. While SSRIs may partially attenuate amphetamine-mediated serotonin release by competing for SERT, the net pharmacodynamic interaction increases serotonin syndrome risk — particularly relevant if 3-FMA retains meaningful serotonergic release activity. The magnitude of 3-FMA's serotonergic potency is unknown.

Lithium in combination with amphetamine-class stimulants lowers the seizure threshold. This interaction is of particular concern given that stimulant-induced seizures are a recognized toxicity endpoint.

methylphenidate, dextroamphetamine, cocaine, high-dose caffeine

Co-administration with other stimulants — including prescription stimulants (methylphenidate, dextroamphetamine), cocaine, and high-dose caffeine — produces additive cardiovascular stress (vasoconstriction, tachycardia) and compounded hyperthermia risk.